{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:20:27Z","timestamp":1776810027520,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6951,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1046\/j.1538-7836.2003.00474.x","type":"journal-article","created":{"date-parts":[[2004,12,26]],"date-time":"2004-12-26T23:53:45Z","timestamp":1104105225000},"page":"2663-2668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux"],"prefix":"10.1016","volume":"1","author":[{"given":"G.J.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.C.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.K.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2165\/00003495-199652050-00007","article-title":"Dexfenfluramine. An updated review of its therapeutic use in the management of obesity","volume":"0","author":"Davis","year":"1996","journal-title":"Drugs"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0015","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. US Department of Health and Human Services interim public health recommendations, November, 1997","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppresant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jama.1997.03550080076043","article-title":"Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence","volume":"278","author":"McCann","year":"1997","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.CIR.99.1.156","article-title":"Aminorex to fen\/phen. An epidemic foretold","volume":"99","author":"Fishman","year":"1999","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"New Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00000441-200104000-00008","article-title":"Appetite suppressants and valvular heart disease","volume":"321","author":"Weissman","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0045","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0165-6147(99)01389-9","article-title":"Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?","volume":"20","author":"MacLean","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(93)90499-8","article-title":"Evidence of an exocytotic-like release of [3H]-5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes","volume":"238","author":"Gobbi","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0055","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1046\/j.1471-4159.1994.63031163.x","article-title":"Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism","volume":"63","author":"Bonanno","year":"1994","journal-title":"J Neurochem"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0022-3565(25)09524-2","article-title":"In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia","volume":"273","author":"Raiteri","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0065","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.CIR.100.8.869","article-title":"Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension","volume":"100","author":"Rothman","year":"1999","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0070","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1172\/JCI10230","article-title":"A role for the serotonin transporter in hypoxia-induced pulmonary hypertension","volume":"105","author":"Fanburg","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0002-9343(90)90111-P","article-title":"Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin","volume":"89","author":"Herve","year":"1990","journal-title":"Am J Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0085","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.ATV.20.10.2233","article-title":"High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy","volume":"20","author":"K\u00e9reveur","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0076-6879(92)15065-K","article-title":"Platelet serotonin transporter","volume":"215","author":"Rudnick","year":"1992","journal-title":"Methods Enzymol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0095","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1016\/S0021-9258(19)85751-4","article-title":"Evidence for two distinct serotonin transport systems in platelets","volume":"255","author":"Rudnick","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0100","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1016\/S0021-9258(19)68584-4","article-title":"Serotonin transport in isolated platelet granules. Coupling to the electrochemical proton gradient","volume":"256","author":"Carty","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0026-895X(25)15042-6","article-title":"Storage of biogenic amines in intact blood platelets of man. Dependence on a proton gradient","volume":"22","author":"Affolter","year":"1982","journal-title":"Mol Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0110","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1016\/S0021-9258(19)83830-9","article-title":"Bioenergietcs of serotonin transport by membrane vesicles derived from platelet dense granules","volume":"257","author":"Fishkes","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0026-895X(25)13357-9","article-title":"Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters","volume":"44","author":"Schuldiner","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1476-5381.1975.tb07395.x","article-title":"Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets","volume":"53","author":"Buczko","year":"1975","journal-title":"Br J Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(77)90287-4","article-title":"Effects of mazindol and d-fenfluramine on 5-hydroxytryptamine uptake, storage and metabolism in blood platelets","volume":"42","author":"Picotti","year":"1977","journal-title":"Eur J Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00547426","article-title":"Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days","volume":"29","author":"Caccia","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0135","first-page":"684","article-title":"The pharmacokinetics of dexfenfluramine in obese and non-obese subjects","volume":"39","author":"Cheymol","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0014-5793(69)80108-0","article-title":"Uptake of serotonin in blood platelets: dependence on sodium and chloride, and inhibition by choline","volume":"3","author":"Lingjaerde","year":"1969","journal-title":"FEBS Letters"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0145","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0021-9258(19)68170-6","article-title":"Coupling of transmembrane proton gradients to platelet serotonin transport","volume":"257","author":"Keyes","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0150","first-page":"7","article-title":"The pharmacologic profile of fluoxetine","volume":"46","author":"Stark","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0155","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1172\/JCI116855","article-title":"Thromboxane-insensitive dog platelets have impaired activation of phospholipase c due to receptor-linked G protein dysfunction","volume":"92","author":"Johnson","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-2143(99)90114-2","article-title":"Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?","volume":"134","author":"MacLean","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/00498259209046620","article-title":"Single- and multiple-dose kinetics of d-fenfluramine in rats given anorectic and toxic doses","volume":"22","author":"Caccia","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF00167450","article-title":"Anorectic effect and brain concentrations of d-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms","volume":"347","author":"Caccia","year":"1993","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0175","first-page":"1306","article-title":"Fenfluramine overdosage","volume":"2","author":"Fleisher","year":"1969","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0180","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0002-9343(02)01123-3","article-title":"Appetite suppressants and valvular heart disease in a population-based sample: the hyperGEN study","volume":"112","author":"Palmieri","year":"2002","journal-title":"Am J Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0190","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)00896-6","article-title":"Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin","volume":"85","author":"Rothman","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0195","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI200112805","article-title":"Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension","volume":"108","author":"Eddahibi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200108023450502","article-title":"Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred","volume":"345","author":"Newman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0205","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/01.CIR.94.9.2216","article-title":"Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction","volume":"94","author":"Weir","year":"1996","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0210","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine. A randomized controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","article-title":"Absence of cardiac valve dysfunction in obese patients treated with sibutramine","volume":"7","author":"Bach","year":"1999","journal-title":"Obes Res"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0220","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mhj.2002.124403","article-title":"Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction","volume":"144","author":"Zannad","year":"2002","journal-title":"Am Heart J"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","article-title":"Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations","volume":"117","author":"Redfield","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0230","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0235","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1046\/j.1538-7836.2003.00474.x_bb0240","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4065\/77.12.1275","article-title":"Drug-related valvular heart disease: here we go again: will we do better this time? Editorial","volume":"77","author":"Rahimtoola","year":"2002","journal-title":"Mayo Clin Proc"}],"updated-by":[{"DOI":"10.1111\/j.1538-7836.2004.00945.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000}}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1538-7836.2003.00474.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622156400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622156400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1046\/j.1538-7836.2003.00474.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:27:28Z","timestamp":1761532048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622156400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S1538783622156400"],"URL":"https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00474.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00474.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}